RBD SARS-CoV-2 HBsAg VLP Vaccine / SpyBiotech, Serum Institute of India, Dynavax - LARVOL DELTA

Serum Institute Of India And Dynavax Announce First Participants Dosed In The Phase 1/2 Clinical Trial For A COVID-19 Vaccine (PRNewswire) - "...Serum Institute of India (SIIPL)...has partnered with Dynavax Technologies Corporation...and today jointly announced that the first participants have been dosed in the Phase 1 part of the Phase 1/2 clinical trial evaluating SIIPL's vaccine candidate adjuvanted with CpG 1018 to prevent COVID-19. The Phase 1/2 clinical trial will evaluate the safety and immunogenicity of SIIPL's vaccine candidate...along with Dynavax's advanced adjuvant CpG 1018 plus alum. The Phase 1 portion of the clinical trial will enroll 39 healthy volunteers and post the completion of the study a decision will be taken regarding the dosing of up to 216 subjects in Phase 2."

Trial status • Infectious Disease • Novel Coronavirus Disease

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19 (GlobeNewswire) - "SpyBiotech...today announces that its partner the Serum Institute of India (SIIPL) has dosed the first subjects in a Phase I/II trial of a novel virus-like particle (VLP) vaccine targeting COVID-19. SpyBiotech has signed an exclusive global licensing agreement with SIIPL....The Phase I/II study has been initiated in Australia. The vaccine candidate uses SpyBiotech’s proprietary SpyCatcher/SpyTag protein 'superglue' technology to display the coronavirus spike protein on the surface of Hepatitis B surface antigen (HBsAg) VLPs."

Licensing / partnership • Trial status • Infectious Disease • Novel Coronavirus Disease